Moreover, the early identification of women who carry pathogenic or likely pathogenic germline variants in BRCA1 or BRCA2 genes will allow the setup of an appropriate diagnostic-therapeutic path to improve the overall survival rate of breast cancer patients. This evidence concerns the gene BRCA1 and breast cancer.